StockIQ.techPenumbra, Inc. (PEN) Stock Analysis
Free AI-powered analysis and research for Penumbra, Inc. stock
Sector: Healthcare
PEN snapshot
Data as of 3 Nov 2026 close. Updated daily.
Penumbra, Inc. scores 63/100 on StockIQ's model, which reads as positive signals overall. The price is below its 200-day average and at 71% of its 52-week range, up 41.9% over the past year. Latest reported figures show a profit margin of 10.1%, return on equity of 10.7% and revenue growth of +15.6%.
What is driving the score
- RSI Neutral: +5
- Flat Trend: +1
- MACD Bearish: -8
- High P/E (80.3): -10
- Strong Revenue Growth (15.6%): +8
- Good Profit Margin (10.1%): +5
- Low Debt (0.13 D/E): +8
- Strong Liquidity (5.89 Current Ratio): +8
- High P/B (7.94): -5
- Below MA200: -4
- Strong Momentum (+41.9% over 1 year): +8
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full PEN report
Penumbra, Inc. (PEN) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze PEN Now →📰 Latest Update
Penumbra (PEN) Stock Faces Q3 Earnings Valuation Scrutiny
Sat, October 31, 2026 at 2:13 PM UTC 4 min read
Penumbra (PEN) is under scrutiny following its Q3 earnings report, which raised concerns about its valuation amid mixed financial results. Investors are closely watching the company's performance as it navigates challenges in the medical device sector, impacting its growth prospects. The market's reaction to these earnings could influence PEN's stock trajectory, making it crucial for investors to assess the implications for future profitability and market confidence.